A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial). (23rd October 2022)

• Record Type: Journal Article
• Authors: Murofushi, Keiko Nemoto; Itasaka, Satoshi; Shimokawa, Mototsugu; Murakami, Yuji; Yamamoto, Takaya; Nishimura, Yasumasa; Kudo, Shigehiro; Sakamoto, Takashi; Ariga, Takuro; Ogo, Etsuyo; Taguchi, Kentaro; Jingu, Keiichi; Ogawa, Kazuhiko
• Is Part Of: Journal of radiation research. Volume 64:Number 1(2023)
• Page Start: 154
• Page End: 161
• Publication Date: 2022-10-23
• Subjects: anal canal cancer -- chemoradiation -- phase II clinical trial -- intensity-modulated radiotherapy (IMRT) -- 3-dimensional conformal radiotherapy (3D-CRT); Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrac069
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: This study assessed the efficacy of chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC). Patients with T1–4N0-3M0 SCCAC received chemoradiotherapy with 5-fluorouracil (5-FU, 800 mg/m 2 /day, 96-h infusion) and mitomycin-C (MMC, 10 mg/m 2 bolus). Patients treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) were administered 36.0 Gy in 20 fractions or 49.5 Gy in 33 fractions for elective nodal irradiation and 59.4 Gy in 33 fractions for primary tumor and metastatic nodal irradiation. The sample size was considered sufficient to estimate 95% confidence intervals (CIs) for the true 2-year disease-free survival (DFS) within a width of +15% when the expected true 2-year DFS was 70%. The primary endpoint was 2-year DFS. The secondary endpoints were 2-year overall survival (OS), locoregional control (LC), colostomy-free survival (CFS) and adverse events. Thirty-one patients were enrolled between January 2014 and July 2019. The median follow-up was 33.3 months (range, 16.2–65.8 months). Among the 31 patients, 13%, 32%, 16% and 39% had stage I, II, IIIA and IIIB disease, respectively. Thirty patients were treated with IMRT. Complete response (CR) was achieved in 27 patients. The 2-year DFS, OS, LC and CFS rates were 77.4% (95% CI, 58.4–88.5%), 93.5% (95% CI, 76.6–98.3%), 83.9% (95% CI, 65.5–92.9%) and 80.6% (95% CI, 61.9–90.8%), respectively. One patient experienced grade 3 late adverse events; however, no grade ≥ 4 late adverse events occurred. Good DFS with a low rate of late adverse events was observed. Chemoradiotherapy with 5-FU and MMC was effective for SCCAC.